PMID- 34114438
OWN - NLM
STAT- MEDLINE
DCOM- 20230503
LR  - 20230503
IS  - 1827-1669 (Electronic)
IS  - 0026-4806 (Linking)
VI  - 114
IP  - 2
DP  - 2023 Apr
TI  - Evaluation of tolerability and major factors affecting the adherence to probiotic 
      therapy in patients with irritable bowel syndrome: a prospective, observational, 
      real-life study.
PG  - 203-209
LID - 10.23736/S0026-4806.21.07015-4 [doi]
AB  - BACKGROUND: Probiotics have been evaluated in multiple clinical trials on 
      irritable bowel syndrome (IBS). However, in real-life long-term compliance could 
      be low. Our study is single-center, observational and prospective, aiming both to 
      evaluate the adherence to prescription of probiotic therapy in real-life and to 
      identify factors able to influence adherence to therapy. METHODS: Fifty patients 
      diagnosed with IBS according to Rome IV and receiving a clinical prescription of 
      a multistrain probiotic preparation (VSL#3((R)) manufactured by Nutrilinea Srl and 
      marketed in Italy by Ferring S.p.A., Milan, Italy) have been enrolled and 49 
      completed the follow-up. Two months after baseline a second visit was made to 
      assess adherence and eventual reasons for discontinuation. RESULTS: Sixty percent 
      of patients took all the prescribed probiotic therapy in real-life setting, with 
      perceived benefits in more than 60% of cases. Among the 20 patients with reduced 
      adherence, 5 took less than 50%, 12 took 50% and 2 took more than 50% but less 
      than 80% of the prescribed doses. Principal reasons of not complete adherence 
      among the 20 patients were: price of the product (8/20), mild adverse events 
      (AEs) (6/20) and poor appreciation of flavour (3/20). CONCLUSIONS: This study 
      suggested that the adherence to probiotic therapy is affected by different 
      factors in patients with IBS in a real-life setting. The main reason for lack of 
      adherence was the price of the product. Other reasons are mild AEs (mainly 
      bloating) and low palatability.
FAU - Laterza, Lucrezia
AU  - Laterza L
AD  - CEMAD Digestive Disease Center, IRCCS A. Gemelli University Polyclinic 
      Foundation, Sacred Heart Catholic University, Rome, Italy.
FAU - Napoli, Marco
AU  - Napoli M
AD  - CEMAD Digestive Disease Center, IRCCS A. Gemelli University Polyclinic 
      Foundation, Sacred Heart Catholic University, Rome, Italy.
FAU - Petito, Valentina
AU  - Petito V
AD  - CEMAD Digestive Disease Center, IRCCS A. Gemelli University Polyclinic 
      Foundation, Sacred Heart Catholic University, Rome, Italy.
FAU - Scaldaferri, Franco
AU  - Scaldaferri F
AD  - CEMAD Digestive Disease Center, IRCCS A. Gemelli University Polyclinic 
      Foundation, Sacred Heart Catholic University, Rome, Italy.
FAU - Gaetani, Eleonora
AU  - Gaetani E
AD  - CEMAD Digestive Disease Center, IRCCS A. Gemelli University Polyclinic 
      Foundation, Sacred Heart Catholic University, Rome, Italy.
FAU - Gasbarrini, Antonio
AU  - Gasbarrini A
AD  - CEMAD Digestive Disease Center, IRCCS A. Gemelli University Polyclinic 
      Foundation, Sacred Heart Catholic University, Rome, Italy - 
      antonio.gasbarrini@unicatt.it.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20210611
PL  - Italy
TA  - Minerva Med
JT  - Minerva medica
JID - 0400732
SB  - IM
MH  - Humans
MH  - *Irritable Bowel Syndrome/diagnosis/drug therapy
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - *Probiotics/therapeutic use
MH  - *Complementary Therapies
EDAT- 2021/06/12 06:00
MHDA- 2023/05/03 06:42
CRDT- 2021/06/11 07:26
PHST- 2023/05/03 06:42 [medline]
PHST- 2021/06/12 06:00 [pubmed]
PHST- 2021/06/11 07:26 [entrez]
AID - S0026-4806.21.07015-4 [pii]
AID - 10.23736/S0026-4806.21.07015-4 [doi]
PST - ppublish
SO  - Minerva Med. 2023 Apr;114(2):203-209. doi: 10.23736/S0026-4806.21.07015-4. Epub 
      2021 Jun 11.